EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma

Yanyan Zhang, Weiqi Wu, Caixia Xu, Hongwei Yang, Guofu Huang

Investigative Opthalmology & Visual Science · 2024

DOI: 10.1167/iovs.65.2.34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigative Opthalmology & Visual Science, 2024. Verfasst von Yanyan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, PR China. Hauptthemen laut MEDLINE: Retinoblastoma, Retinal Neoplasms, Benzazepines, Pyrimidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to investigate the antitumor effects of GSK-J4 on retinoblastoma, as well as its related biological functions and molecular mechanisms.

Methods

The antitumor effect of GSK-J4 on retinoblastoma was evaluated by in vitro and in vivo assays. CCK-8, EdU incorporation, and soft agar colony formation assays were performed to examine the effect of GSK-J4 on cell proliferation. Flow cytometry was used to evaluate the effect of GSK-J4 on the cell cycle and apoptosis. RNA-seq and Western blotting were conducted to explore the molecular mechanisms of GSK-J4. An orthotopic xenograft model was established to determine the effect of GSK-J4 on tumor growth.

Results

GSK-J4 significantly inhibited retinoblastoma cell proliferation both in vitro and in vivo, arrested the cell cycle at G2/M phase, and induced apoptosis. Mechanistically, GSK-J4 may suppress retinoblastoma cell growth by regulating the PI3K/AKT/NF-κB signaling pathway.

Conclusions

The antitumor effects of GSK-J4 were noticeable in retinoblastoma and were at least partially mediated by PI3K/AKT/NF-κB pathway suppression. Our study provides a novel strategy for the treatment of retinoblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaRetinal NeoplasmsBenzazepinesPyrimidinesHumansHistone DemethylasesNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCell ProliferationCell Line, TumorApoptosis

Substanzen

Histone DemethylasesGSK-J4NF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktBenzazepinesPyrimidines

Autor:innen und Institutionen

  • Department of Ophthalmology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, PR China.
  • Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, PR China.
  • Jiangxi Provincial Key Laboratory of Tumor Metastasis and Precision Therapy, Center Laboratory, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, PR China.
  • Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, PR China.

Zitieren

APA

Zhang, Y., Wu, W., Xu, C., Yang, H., & Huang, G. (2024). Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.65.2.34

Vancouver

Zhang Y, Wu W, Xu C, Yang H, Huang G. Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma. Investigative Opthalmology & Visual Science. 2024. doi:10.1167/iovs.65.2.34

BibTeX
@article{Zhang2024,
  author = {Zhang, Yanyan and Wu, Weiqi and Xu, Caixia and Yang, Hongwei and Huang, Guofu},
  title = {Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2024},
  doi = {10.1167/iovs.65.2.34}
}
Kostenlos starten →